GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome
暂无分享,去创建一个
[1] Julie Brown,et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. , 2016, The Cochrane database of systematic reviews.
[2] W. Martins,et al. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[3] Keren Amichay,et al. GnRH-antagonist programming versus GnRH agonist protocol: a randomized trial. , 2015, European journal of obstetrics, gynecology, and reproductive biology.
[4] B. Tarlatzis,et al. Serum vascular endothelial growth factor levels following luteal gonadotrophin‐releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome , 2014, BJOG : an international journal of obstetrics and gynaecology.
[5] P. Devroey,et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. , 2014, Fertility and sterility.
[6] B. Sancak,et al. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. , 2014, European journal of obstetrics, gynecology, and reproductive biology.
[7] W. Martins,et al. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. , 2014, Fertility and sterility.
[8] R. Orvieto. Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma , 2013, Journal of Ovarian Research.
[9] B. Tan,et al. Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee , 2013, Human fertility.
[10] B. Tan,et al. Management of Ovarian Hyperstimulation Syndrome Guidelines. Produced on behalf of the BFS Policy and Practice Committee , 2013, Human fertility.
[11] P. Humaidan,et al. GnRH agonist triggering: recent developments. , 2013, Reproductive biomedicine online.
[12] P. Patrizio,et al. GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate. , 2013, Reproductive biomedicine online.
[13] S. Palomba,et al. Pronuclear morphology evaluation in in vitro fertilization (IVF) / intracytoplasmic sperm injection (ICSI) cycles: a retrospective clinical review , 2013, Journal of Ovarian Research.
[14] D. Ezcurra,et al. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment , 2012, Reproductive Biology and Endocrinology.
[15] J. García-Velasco. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. , 2012, Fertility and sterility.
[16] S. Zhai,et al. Cabergoline for preventing ovarian hyperstimulation syndrome. , 2012, The Cochrane database of systematic reviews.
[17] P. Claman,et al. The diagnosis and management of ovarian hyperstimulation syndrome. , 2011, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.
[18] P. Devroey,et al. An OHSS-Free Clinic by segmentation of IVF treatment. , 2011, Human reproduction.
[19] A. Abou-Setta,et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology in women with poor ovarian response. subgroup analysis of cochrane systematic review and meta-analysis , 2011 .
[20] A. Pellicer,et al. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. , 2011, Fertility and sterility.
[21] G. Griesinger,et al. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. , 2011, Fertility and sterility.
[22] P. Bossuyt,et al. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. , 2007, Human reproduction.
[23] J. Lessing,et al. [Ovarian hyperstimulation syndrome]. , 1995, Harefuah.
[24] N. Amso,et al. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. , 2017, The Cochrane database of systematic reviews.
[25] S. Sunkara,et al. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. , 2014, Human reproduction update.
[26] P. Talwar,et al. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status. , 2014, Medical journal, Armed Forces India.
[27] Mature Oocyte. Mature oocyte cryopreservation: a guideline The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted , 2012 .
[28] V. Senikas,et al. JOINT SOGC-CFAS CLINICAL PRACTICE GUIDELINE The diagnosis and management of ovarian hyperstimulation syndrome ☆ , 2012 .
[29] F. Broekmans,et al. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. , 2011, Human reproduction update.
[30] M. Gysler,et al. JOINT SOGC-CFAS CLINICAL PRACTICE GUIDELINE , 2010 .